Theravance Biopharma Inc Net Asset Quality Index
Theravance Biopharma Inc net asset quality index. Theravance Biopharma Inc (TBPH) has a Net Asset Quality Index of 61.1% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $485.57 Million minus total liabilities of $188.85 Million yields net assets of $296.72 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check TBPH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Theravance Biopharma Inc (2011–2025)
Net asset quality index of Theravance Biopharma Inc from 2011 to 2025. This chart shows how Theravance Biopharma Inc's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the index stands at 61.1%, representing net assets of $296.72 Million against total assets of $485.57 Million USD. See TBPH net assets for net asset value and shareholders' equity analysis.
Theravance Biopharma Inc Net Asset Quality Index by Year (2011–2025)
Theravance Biopharma Inc net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Theravance Biopharma Inc from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Theravance Biopharma Inc.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 61.1% | $296.72 Million | $485.57 Million | $188.85 Million | ▲ +11.5 pp |
| 2024 | 49.6% | $175.54 Million | $354.16 Million | $178.62 Million | ▼ -6.2 pp |
| 2023 | 55.8% | $213.00 Million | $382.00 Million | $169.00 Million | ▼ -17.0 pp |
| 2022 | 72.7% | $441.80 Million | $607.40 Million | $165.60 Million | ▲ +163.1 pp |
| 2021 | -90.3% | $-338.57 Million | $374.82 Million | $713.39 Million | ▼ -25.6 pp |
| 2020 | -64.8% | $-303.75 Million | $469.06 Million | $772.81 Million | ▼ -10.0 pp |
| 2019 | -54.8% | $-223.84 Million | $408.83 Million | $632.67 Million | ▼ -45.5 pp |
| 2018 | -9.2% | $-51.59 Million | $560.24 Million | $611.82 Million | ▼ -35.3 pp |
| 2017 | 26.1% | $115.18 Million | $441.40 Million | $326.22 Million | ▼ -28.7 pp |
| 2016 | 54.8% | $350.23 Million | $639.25 Million | $289.02 Million | ▼ -26.2 pp |
| 2015 | 81.0% | $243.06 Million | $300.12 Million | $57.05 Million | ▼ -4.8 pp |
| 2014 | 85.8% | $289.79 Million | $337.77 Million | $47.98 Million | ▲ +153.5 pp |
| 2013 | -67.7% | $-17.04 Million | $25.18 Million | $42.21 Million | ▼ -59.5 pp |
| 2012 | -8.2% | $-1.71 Million | $20.96 Million | $22.67 Million | ▲ +1010.0 pp |
| 2011 | -1018.2% | $-140.72 Million | $13.82 Million | $154.54 Million | — |